Energy & Sustainability Goal Setting: Climate Action

Multimedia with summary

Ambitious Climate Action – Science-Based Targets
Led by the Science-Based Targets Initiative, a collaboration between CDP, the UN Global Compact, WRI and WWF

Corporate Responsibility Association and CR Magazine Announce Commit!Forum 2017 Theme; ‘Brands Taking Stands’ to Drive Discussion, Oct. 11-12 in Washington’s National Harbor

BrownFlynn hosts pre-conference workshop on reporting, Oct. 10
Press Release

WASHINGTON, D.C., July 10, 2017 /3BL Media/ – The Corporate Responsibility Association (CRA) and CR Magazine announced today the 2017 edition of COMMIT!Forum will focus on “Brands Taking Stands, the role of the corporate responsibility practitioner as companies make their voices heard.

Pricing Our Medicines to Help Ensure Patient Access


We know there is significant frustration in the US regarding the cost of healthcare – including prescription medicines. We take this very seriously, as evidenced by our pricing track record. In fact, the launch price of our six most recently introduced new medicines were priced similarly or less than the market leader. This illustrates our commitment to appropriately balance reward for our innovation and ensure broadest patient access.

Building Future Leaders


Everyone talks about “leadership.” Business schools teach courses on it and war metaphors abound. Great leaders are often described as near-mythical creatures - like unicorns. Yet we believe that what makes someone a leader is a combination of both nature and nurture – and, perhaps most importantly, opportunity.

Building our future leaders

We’re not waiting for unicorns to move our story forward. Instead, we’re building our future leaders and creating the opportunities for them to succeed.

Changing the Way We Do Business


When was the last time you upended your life – reevaluated the way you work, radically shifted how you measure success – and convinced 100,000 people to do it with you?

Now consider how the pharmaceutical industry traditionally markets and sells its products:

Designing Inspiring and Healthy Workplaces


As a healthcare company, we focus on how we can best support the wellbeing of patients, consumers, and our employees. We aim to create healthy, safe and inclusive workplaces where everyone at GSK can feel energized and inspired to realize their potential and help us meet global health challenges. And this means rethinking the physical structures where we spend much of our time.

Place matters to health

Putting It Plainly


Historically, our industry has struggled to embrace the idea of transparency, citing the need to remain competitive. Increasingly, however, we see that physicians, patients, policy makers, and the general public expect our industry to lift its veil — especially on clinical research. And, in our opinion, being transparent is not a path to failure — it is a source of strength.

Letting the light in

Fast-Tracking Our Response to Pandemics


In the wake of global pandemics such as Ebola and Zika, there is consensus that the world needs to be better prepared.

Finding better ways to prepare

Helping Patients in Need


Insurance coverage can be challenging, financial circumstances can change quickly, and sometimes patients need assistance paying for their prescription medications or vaccines.

Helping patients access the GSK medicines and vaccines they need is critically important to us and aligns with our value of being a patient-focused company.

Paying for your prescription

For those patients in the US who are eligible, we help them:

Evolving Our Graduated Approach to Intellectual Property


In developing countries, millions of people have no access to even the most basic healthcare services, including safe and effective medicines. Increasingly, developing countries are hit with the double burden of infectious diseases such as HIV/AIDS, tuberculosis, and malaria, and the growing problem of non-communicable diseases (NCDs) such as diabetes and cancer.

A graduated approach to intellectual property


Subscribe to GlaxoSmithKline